Comparison of anti-VEGF results between non-ischemic branch retinal vein occlusion and ischemic branch retinal vein occlusion with early sector panretinal photocoagulation Comparaison des résultats des anti-VEGF entre occlusion veineuse rétinienne de branche non ischémique et occlusion ischémique avec photocoagulation rétinienne périphérique précoce
Journal Francais d'Ophtalmologie, cilt.45, sa.9, ss.1042-1047, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 45 Sayı: 9
- Basım Tarihi: 2022
- Doi Numarası: 10.1016/j.jfo.2022.03.014
- Dergi Adı: Journal Francais d'Ophtalmologie
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.1042-1047
- Anahtar Kelimeler: Branch retinal vein occlusion, Laser photocoagulation, Macular edema, Ranibizumab, Retina
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To compare the need for anti-vascular endothelial growth factor (VEGF) in treating macular edema (ME) in patients with non-ischemic branch retinal vein occlusion (BRVO) and patients with ischemic BRVO with early peripheral photocoagulation. Methods: Patients with BRVO with ME were included in the retrospective study. The patients were divided into two groups according to peripheral ischemic status: a non-ischemic BRVO group and an ischemic BRVO group. All patients received three initial monthly 0.50 mg ranibizumab injections followed by a pro re nata (PRN) regimen. In the ischemic BRVO group, early peripheral laser photocoagulation was applied in the area of capillary nonperfusion as defined by fluorescein angiography. The mean change in central macular thickness (CMT), best-corrected visual acuity (BCVA), and number of injections were evaluated. Results: Fifty-seven eyes of 57 patients were included in the study (32 nonischemic BRVO; 25 ischemic BRVO). Mean follow-up was 20.0 (SD,4.9) months. The mean number of injections from baseline to final visit was 5.3 (SD 3.4) and 4.6 (SD 2.6) for the nonischemic BRVO group and ischemic BRVO group, respectively. This difference was not statistically significant (P = 0.48). There was no significant difference in CMT and BCVA between groups. Conclusion: No difference in the need for anti-VEGF therapy was observed between patients with non-ischemic BRVO and patients with ischemic BRVO with early laser photocoagulation.